Table 1.
Participating Institutions.
Table 2.
Eligibility criteria for the study.
Fig 1.
Treatment protocols planned for the study.
Arrows indicate administration time points within each treatment arm. GEM, gemcitabine; GS, gemcitabine and S-1; GS-RT, gemcitabine and S-1 with concurrent radiotherapy.
Fig 2.
This figure summarizes participant timeline throughout the study period, including enrollment, neoadjuvant gemcitabine and S-1 (GS or GS-RT) treatment, preoperative evaluation, surgery, and postoperative follow-up.GS, gemcitabine and S-1; GS-RT, gemcitabine and S-1 with concurrent radiotherapy.